News Contact Us

The ICMR reports Remdesivir to work against COVID-19 replication

Author : Saipriya Iyer | Published Date : 2020-04-14 

The ICMR (Indian Council of Medical Research), the apex biomedical research authority of India, has reportedly stated that an antiviral drug, remdesivir, may turn out to be highly effective to stop the replication of SARS CoV-2, the virus that is responsible for causing coronavirus. Remdesivir was previously used at the time of the Ebola outbreak.

The ICMR stated that research regarding the safety and efficacy to treat COVID-19 is part of a WHO’s Solidarity Trial.

As per a recent study published in the New England Journal of Medicine, two of the three critical coronavirus infected patients relying on ventilators or oxygen support showed improvement when remdesivir was administered to them.

Speaking on the research, Raman R Gangakhedkar, Head of the Epidemiology and Communicable diseases, ICMR stated that remdesivir, which was utilized against Ebola, also restricts reproduction of COVID-19 as per the researchers, which is a prime factor for it to be effective for the treatment of COVID-19.

Gangakhedkar further added that recently reported study on the use of this drug for coronavirus treatment was not a clinical study, but an observational study. From this study, the researchers found that about 68 percent or two of three patients after the administration of remdesivir did not need ventilators or the amount of oxygen support they required decreased. More about the drug efficiency would be known from the WHO Solidarity Trial, which has a division looking into this.

Gilead Sciences Inc. develops the antiviral drug remdesivir, however, it is currently not available in the nation. The Indian government is working to see whether any pharma company can produce this drug locally.

India is seeing a steady growth in the number of COVID-19 patients every day. The number of cases in the country has surged to 9,352 while the death toll has reached 324 as per the stats provided by the Union Health Ministry on Monday. However, according to a PTI tally of the numbers provided by several states on Monday, at least 9,975 people were infected while 346 casualties were reported.   


Source credit: https://www.news18.com/news/india/antiviral-drug-remdesivir-may-be-effective-in-stopping-replication-of-coronavirus-icmr-2576601.html

About Author

Saipriya Iyer

Saipriya Iyer

Saipriya Iyer presently works as a content developer for fractovia.org. Having dabbled with the domain of content creation for nearly half a decade, she now boasts of an enviable portfolio, holding substantial experience in penning down pieces related to technology, finance, and a wide spectrum of other industry verticals. A qualified computer engineering graduate from the University of Pune, Saipriya can often be found leveraging her knowledge of software technology and electronics in her write-ups. She can be contacted at- [email protected] | https://twitter.com/saipriya_i

Related News

Virgin Atlantic files for bankruptcy due to low air travel demand

Published Date: 2020-08-06         Author: Saipriya Iyer

Virgin Atlantic, a British airline, is currently seeking protection under Chapter 15 of the United States bankruptcy code. This announcement also marks the struggle faced by numerous carriers, including Australia’s 2nd largest airline, Virgin Australia, to survive amid severe decline in air... Read More

NHS England invests £160M on new ‘COVID-friendly’ cancer drugs

Published Date: 2020-08-04         Author: Saipriya Iyer

NHS England is reportedly investing £160 million on new ‘COVID-friendly’ cancer drugs that are less likely to impact the patients’ immune system. The drugs can also be prescribed for patients at home to reduce their instances of visiting the hospitals, which will allow them t... Read More

Kodak share soars post active drug ingredient development deal

Published Date: 2020-07-30         Author: Saipriya Iyer

Shares of Eastman Kodak, an American technology company, have recently increased, following the announcement of a deal by the U.S. President Donald Trump. The agreement is regarding the President’s collaboration with the company to produce active ingredients for generic medicines to fight agai... Read More

© 2020 Fractovia. All Rights Reserved